ArticleInternational journal of technology assessment in health care2013
Relationship between financial impact and coverage of drugs in Australia.
Article in International journal of technology assessment in health care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.PharmacoEconomics · 2018Pooled it
- Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia.PharmacoEconomics · 2025Article
- Methods and Practical Considerations for Conducting Budget Impact Analysis for Non-Pharmaceutical Interventions.Applied health economics and health policy · 2025Review
- Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee.PharmacoEconomics · 2024Review
- The role of budget impact and its relationship with cost-effectiveness in reimbursement decisions on health technologies in the Netherlands.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (MaviretInfectious diseases and therapy · 2024Article
- Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria.Frontiers in pharmacology · 2021Article
- Empirical Monetary Valuation of a Quality-Adjusted Life-Year in the Kingdom of Saudi Arabia: A Willingness-to-Pay Analysis.PharmacoEconomics - open · 2020Article
- Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Article
- The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).PharmacoEconomics · 2018Review
- WHO guide on the economic evaluation of influenza vaccination.Influenza and other respiratory viruses · 2018Review
- The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges.The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.ClinicoEconomics and outcomes research : CEOR · 2018Review
- A Methodological Review of US Budget-Impact Models for New Drugs.PharmacoEconomics · 2016Review
- Assessing the Value of New Treatments for Hepatitis C: Are International Decision Makers Getting this Right?PharmacoEconomics · 2016Article
- Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.Frontiers in public health · 2016Article
- Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion.Frontiers in pharmacology · 2016Article
- Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold.ClinicoEconomics and outcomes research : CEOR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to estimate the relationship between the financial impact of a new drug and the recommendation for reimbursement by the Australian Pharmaceutical Benefits Advisory Committee (PBAC).
methodsData in the PBAC summary database were abstracted for decisions made between July 2005 and November 2009. Financial impact-the upper bound of the values presented in the PBAC summary database-was categorized as ≤A$0, >A$0 up to A$10 million, A$10 million up to A$30 million, and >A$30 million per year. Descriptive, logistic, survival, and recursive partitioning decision analyses were used to estimate the relationship between the financial impact of a new drug indication and the recommendation for reimbursement. Multivariable analyses controlled for other clinical and economic variables, including cost per quality-adjusted life-year gained.
resultsFinancial impact was a significant predictor of the recommendation for reimbursement. In the logistic analysis, the odds ratios of reimbursement for drug submissions with financial impacts ≥A$10 million to ≥A$30 million or >A$0 to <A$10 million compared with ≤A$0 were 0.12 (95 percent confidence interval [CI]: 0.03-0.51) and 0.16 (95 percent CI: 0.04-0.60), respectively. In the recursive partition decision analysis, the first split of the data was for submissions with a positive financial impact compared with those with a zero or negative financial impact.
conclusionsIn Australia, financial impact on the drug budget is an important determinant of whether a new drug is recommended for reimbursement when cost-effectiveness estimates and other clinical and economic variables are controlled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.